Fig. 4From: Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case reportPathological examination of postoperative tumor tissue revealed of lung adenocarcinoma and immunostaining of PD-L1 (a) and MMR-related proteins, including MSH2 (b), MSH6 (c), MLH1 (d), and PMS2 (e) in postoperative tumor tissueBack to article page